VivaBio Reports 2026 Interim Performance: AI Leading New Drug Development Paradigm, CDMO Commercial Production Driving High Revenue Growth
August 26, 2026 — 22:25 CST
This Data Is Locked!
This area is available only to Subscribers.
VivaBio Technology Holding Group (1873.HK) revealed its interim performance highlights as of June 30, 2026: total revenue of 1,006.5 million RMB, a year-on-year increase of... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
